Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Ascentage Pharma Group International Cash Ratio?
Ascentage Pharma Group InternationalASPHF 66 Cash Ratio is 1.50 as of Dec. 2025, which is 63% below its 10-year median of 4.02. GuruFocus rates ASPHF with a GF Score™ of 66/100 and a GF Value™ of $7.43 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 1,385 Biotechnology companies, Ascentage Pharma Group International ranks worse than 66.57% on this metric.
Ascentage Pharma Group International has a Cash Ratio of 1.50. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
ASPHF's Cash Ratio is ranked worse than 66.57% of 1385
companies
in the Biotechnology industry
Industry Median: 2.95
vs ASPHF: 1.50
Ascentage Pharma Group International (OTCPK:ASPHF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Ascentage Pharma Group International Cash Ratio Related Terms
Ascentage Pharma Group International Cash Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International Cash Ratio Chart
For the Biotechnology subindustry, Ascentage Pharma Group International's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ascentage Pharma Group International Cash Ratio vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ascentage Pharma Group International (ASPHF) has a Cash Ratio of 1.50 as of Dec. 2025. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Ascentage Pharma Group International and its competitors. This is 63% below median its historical median of 4.02. Over the past decade, Ascentage Pharma Group International's Cash Ratio has ranged from 1.06 to 9.23. According to the industry distribution chart, Ascentage Pharma Group International ranks #922 out of 1385 companies in the Biotechnology industry, placing it in the top 66.6%.
Is Ascentage Pharma Group International's Cash Ratio too high?
Ascentage Pharma Group International's current Cash Ratio of 1.50 is 63% below median its 10-year median of 4.02. Over the past 10 years, this metric has ranged from a low of 1.06 to a high of 9.23. The Biotechnology industry median Cash Ratio is 2.95. Ascentage Pharma Group International's value of 1.50 is 49.2% below this industry median. Based on the distribution chart, Ascentage Pharma Group International ranks #922 out of 1385 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Ascentage Pharma Group International has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ascentage Pharma Group International's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ascentage Pharma Group International ranks #922 out of 1385 companies for Cash Ratio. This places Ascentage Pharma Group International in the lower half of its industry. The industry median Cash Ratio is 2.95. Ascentage Pharma Group International's value of 1.50 is 49.2% below this benchmark. Historically, Ascentage Pharma Group International's own Cash Ratio has ranged from 1.06 to 9.23 over the past decade. While the company's 10-year median is 4.02 vs. the industry median of 2.95, Ascentage Pharma Group International has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.95, based on 1,385 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ascentage Pharma Group International's current Cash Ratio of 1.50 is 49.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Ascentage Pharma Group International and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ascentage Pharma Group International's current Cash Ratio is 1.50, which is 63% below median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ascentage Pharma Group International stock overvalued right now?
Based on GuruFocus' analysis, Ascentage Pharma Group International (ASPHF) is currently considered Possible Value Trap. The stock's GF Value™ is $7.43, compared to a current price of $4.53 — trading 39% below its estimated fair value. The current Cash Ratio is 1.50, which is 63% below median its 10-year median of 4.02 and 49.2% below the Biotechnology industry median of 2.95. Ascentage Pharma Group International's overall GF Score™ is 66/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Ascentage Pharma Group International (ASPHF), the current Cash Ratio is 1.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ascentage Pharma Group International (ASPHF) Overvalued in 2026?
Based on GuruFocus' analysis, Ascentage Pharma Group International stock appears to be undervalued.
The current stock price of $4.53 is trading 39% below its estimated GF Value™ of $7.43.
GuruFocus considers Ascentage Pharma Group International to be Possible Value Trap.
Key valuation signals for ASPHF:
Cash Ratio: 1.50 (63% below median its 10-year median of 4.02)
GF Value™: $7.43 vs. price of $4.53 (39% below fair value)
Industry Position: 49.2% below the Biotechnology median (#922 of 1385)
No single metric tells the full story. See the ASPHF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ascentage Pharma Group International Business Description
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
66GF Score
Get the complete analysis for ASPHF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASPHF has been successfully added to your 
